FIELD: medicine; pharmaceuticals.
SUBSTANCE: presented group of inventions refers to pharmaceutical industry, namely to an agent for treating cancer. Pharmaceutical composition for treating cancer, comprising: micronized particles of compound A and/or micronized particles of at least one pharmaceutically acceptable salt of compound A and at least one pharmaceutically acceptable excipient, wherein said micronised particles of compound A and/or micronized particles of at least one pharmaceutically acceptable salt of compound A have particle size distribution (PSD) D90 of less than or equal to 20 mcm, wherein said compound A is N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulphonamide, presented by formula
(embodiments).
Use of the pharmaceutical composition for preparing a drug for treating cancer. Micronized particles of compound A and/or micronized particles of at least one pharmaceutically acceptable salt of compound A (embodiments). Use of micronized particles of compound A for preparing a drug for treating cancer. Method of treating a subject for which the need to treat cancer is recognized, comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition or micronized particles of compound A.
EFFECT: compositions described above and micronized particles of compound A are characterized by high AUC value in the dosage form, low toxicity, using them reducing cases of vomiting in treating cancer diseases.
26 cl, 8 dwg, 12 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTIC COMPOSITION CONTAINING OMAGACARBOXYARYL-SUBSTITUTED DIPHENYL UREA FOR CANCER TREATMENT | 2006 |
|
RU2420283C2 |
SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUBSTITUTED INDANE, AND METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2772693C1 |
POLYMORPHIC FORMS OF ST-246 COMPOUND AND METHODS FOR PRODUCING | 2011 |
|
RU2578606C2 |
LOW-DOSE PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN FOR ORAL ADMINISTRATION | 2015 |
|
RU2707753C2 |
PHARMACEUTICAL COMPLEX COMPOSITION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2016 |
|
RU2724338C2 |
METHODS OF INHIBITING LEUCOTREEN-A-HYDROLASES | 2014 |
|
RU2686101C2 |
COMPOSITIONS AND METHODS OF TREATING ANDROGEN-RECEPTOR-POSITIVE CANCER | 2020 |
|
RU2817802C2 |
PHARMACEUTICAL COMPOSITIONS OF SUBSTITUTED QUINAZOLINONES | 2012 |
|
RU2640115C2 |
PHARMACEUTICAL COMPOSITION CONTAINING PARP INHIBITORS | 2019 |
|
RU2785677C1 |
SOLID PHARMACEUTICAL PREPARATION, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2809722C1 |
Authors
Dates
2020-01-24—Published
2016-05-24—Filed